Skip to content

Study · In vitro (cells) · 2002

3 results

Effects of Livagen peptide on chromatin activation in lymphocytes from old people.

Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IY

Bulletin of experimental biology and medicine1 Oct 2002Cited by 3 (Europe PMC)

PMID12533768 (opens in a new tab)DOI10.1023/a:1021924702103 (opens in a new tab)PepBankPUB-12533768
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In lymphocytes from old people, Livagen activated ribosomal genes.

    In plain wordsIn cells from older people, Livagen activated ribosomal genes.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseRibosomal gene activity
    Study

    humann: not reported in source

    lymphocytes from old people
    Outcome group
    Receptor activity and mechanism · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Livagen induced activation of ribosomal genes
    1 context sentence
    Summary · context
    We studied the effects of the synthetic peptide Livagen on activity of ribosomal genes, denaturation parameters of heterochromatin, polymorphism of structural C-heterochromatin, and variability of facultative heterochromatin in lymphocytes from old people.
  2. 02LabIn vitro (cells)Mechanism

    In lymphocytes from old people, Livagen induced decondensation of pericentromeric structural heterochromatin.

    In plain wordsIn cells from older people, Livagen loosened condensed chromatin near chromosome centers.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreasePericentromeric structural heterochromatin decondensation
    Study

    humann: not reported in source

    lymphocytes from old people
    Outcome group
    Receptor activity and mechanism · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed due to age-related condensation of euchromatic regions in chromosomes.
    1 context sentence
    Summary · context
    We studied the effects of the synthetic peptide Livagen on activity of ribosomal genes, denaturation parameters of heterochromatin, polymorphism of structural C-heterochromatin, and variability of facultative heterochromatin in lymphocytes from old people.
  3. 03LabIn vitro (cells)Mechanism

    In lymphocytes from old people, Livagen released genes repressed by age-related condensation of euchromatic chromosome regions.

    In plain wordsIn cells from older people, Livagen released genes that age-related chromosome condensation repressed.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseRelease of repressed genes
    Study

    humann: not reported in source

    lymphocytes from old people
    Outcome group
    Receptor activity and mechanism · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed due to age-related condensation of euchromatic regions in chromosomes.
    1 context sentence
    Summary · context
    We studied the effects of the synthetic peptide Livagen on activity of ribosomal genes, denaturation parameters of heterochromatin, polymorphism of structural C-heterochromatin, and variability of facultative heterochromatin in lymphocytes from old people.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.